Abaloparatide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store refrigerated at 2-8 degrees C (36-46 degrees F) prior to first use. Do not freeze. After first use, may be stored at room temperature (20-25 degrees C / 68-77 degrees F) for up to 30 days. Discard pen 30 days after first use, even if medication remains.
Protocol Quick-Reference
Osteoporosis in postmenopausal women and men at high fracture risk
Dosing
Amount
80 mcg fixed dose
Frequency
Once daily
Duration
Up to 2 years
Administration
Route
SCSchedule
Once daily
Timing
Same time each day; no food restrictions
โ Rotate injection sites
Cycle
Duration
Up to 2 years cumulative
Repeatable
Single cycle
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Refrigerate at 2-8 degrees C before first use. After first use, store at room temperature (20-25 degrees C) for up to 30 days. Do not freeze.
โ๏ธ Suggested Bloodwork (5 tests)
Serum calcium
When: Baseline
Why: Rule out pre-existing hypercalcemia
25-hydroxyvitamin D
When: Baseline
Why: Ensure adequate vitamin D status before treatment
DEXA bone density scan
When: Baseline
Why: Establish baseline BMD at spine and hip
Serum calcium
When: Periodic monitoring
Why: Monitor for hypercalcemia during treatment
DEXA bone density scan
When: 12-18 months
Why: Assess BMD response to treatment
๐ก Key Considerations
- โFollow with antiresorptive therapy (alendronate or denosumab) after completing abaloparatide to maintain BMD gains
- โEnsure adequate calcium (at least 1000 mg/day) and vitamin D (at least 400 IU/day) supplementation
- โContraindicated in patients with pre-existing hypercalcemia, Paget disease, or unexplained alkaline phosphatase elevation
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Osteoporosis (Postmenopausal Women and Men at High Fracture Risk) | 80 mcg subcutaneous injection once daily. No dose titration required. Fixed dose for all patients. | Once daily subcutaneous injection | Up to 2 years of cumulative use. Treatment should be followed by antiresorptive therapy (e.g., alendronate or denosumab) to maintain BMD gains. | No dose adjustment required for age, body weight, renal impairment, or hepatic impairment. Administer at the same time each day. Calcium and vitamin D supplementation recommended. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Abaloparatide (Tymlos) is supplied as a pre-filled pen device containing 2 mL of solution delivering 30 daily doses of 80 mcg each. No reconstitution, mixing, or dilution is required.
Recommended Injection Sites
- โPeriumbilical region of the abdomen (rotating sites within the area)
๐งStorage Requirements
Store refrigerated at 2-8 degrees C (36-46 degrees F) prior to first use. Do not freeze. After first use, may be stored at room temperature (20-25 degrees C / 68-77 degrees F) for up to 30 days. Discard pen 30 days after first use, even if medication remains.
Community Dosing Protocols
Compare these clinical doses with what 35+ community members report using.
Based on 35+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Prescribing Information#
Abaloparatide (Tymlos) is an FDA-approved prescription medication for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture. All dosing information below is based on FDA-approved prescribing information and the ACTIVE clinical trial protocol. Abaloparatide must be prescribed and supervised by a qualified healthcare provider.
Dosing Protocol#
Fixed Dose#
Abaloparatide is administered as a fixed 80 mcg dose once daily by subcutaneous injection. Unlike some other injectable therapies, no dose titration or escalation is required. All patients receive the same dose regardless of age, body weight, renal function, or hepatic function.
Treatment Duration#
Treatment with abaloparatide is recommended for up to 2 years of cumulative use. The 2-year limitation reflects the duration of clinical trial data available and the class-based precedent from teriparatide (though the osteosarcoma boxed warning was removed from the teriparatide label in 2020).
Sequential Therapy#
Following completion of abaloparatide therapy, patients should transition to an antiresorptive agent to maintain BMD gains. The ACTIVExtend trial demonstrated that abaloparatide followed by alendronate for 24 months preserved and extended the fracture protection achieved during the anabolic phase.
| Treatment Phase | Agent | Duration | Purpose |
|---|---|---|---|
| Anabolic phase | Abaloparatide 80 mcg daily | Up to 18-24 months | Build new bone |
| Antiresorptive phase | Alendronate or denosumab | Ongoing | Maintain BMD gains |
Clinical Outcomes by Timepoint (ACTIVE Trial)#
- 6 months: Significant increases in lumbar spine and total hip BMD versus placebo
- 12 months: Continued BMD accrual at all sites
- 18 months: Vertebral fracture risk reduction 86%, nonvertebral fracture risk reduction 43%
Administration Technique#
Pre-Filled Pen Device#
Tymlos is supplied as a single-patient-use pre-filled pen containing 2 mL of abaloparatide solution (3,120 mcg total), delivering 30 doses of 80 mcg each. The pen uses 31-gauge x 5/16 inch disposable needles (provided separately).
Injection Procedure#
-
Preparation: Remove pen from refrigeration and allow to reach room temperature. Attach a new pen needle. Prime the pen before first use by pressing the injection button until a drop appears.
-
Site selection: Inject into the periumbilical region of the abdomen. Rotate injection sites daily to minimize injection site reactions. Avoid injecting within 2 inches of the navel or into areas with bruising, redness, or hardness.
-
Injection: Insert the needle into a pinched skin fold, press the injection button completely, hold for 10 seconds, then withdraw.
-
Disposal: Remove and discard the pen needle in a sharps container after each injection. Replace the pen cap.
Timing#
- Administer at approximately the same time each day
- No food or fasting requirements
- If orthostatic hypotension occurs, patients may sit or lie down during and after injection
Missed Doses#
If a dose is missed, administer it as soon as possible on the same day. Do not take two doses on the same day.
Storage Requirements#
- Before first use: Refrigerate at 2-8 degrees C (36-46 degrees F). Do not freeze.
- After first use: May be stored at room temperature (20-25 degrees C / 68-77 degrees F) for up to 30 days.
- Pen expiry: Discard the pen 30 days after first use, even if doses remain.
- Keep pen cap on when not in use. Do not store with a needle attached.
Supplementation Requirements#
All patients receiving abaloparatide should take supplemental calcium and vitamin D if dietary intake is inadequate:
- Calcium: At least 1,000 mg daily (from diet and supplements combined)
- Vitamin D: At least 400-800 IU daily; correct any pre-existing vitamin D deficiency before starting therapy
Special Dosing Considerations#
Renal Impairment#
No dose adjustment is recommended for mild to moderate renal impairment. Abaloparatide has not been studied in severe renal impairment (eGFR less than 30 mL/min) or dialysis patients.
Hepatic Impairment#
No dose adjustment required. Abaloparatide is not metabolized by hepatic CYP enzymes.
Elderly Patients#
No dose adjustment required. The ACTIVE trial enrolled patients aged 49-86 years with comparable efficacy and safety across age groups.
Monitoring Recommendations#
| Test | Timing | Purpose |
|---|---|---|
| Serum calcium | Baseline, periodic | Detect hypercalcemia |
| 25-hydroxyvitamin D | Baseline | Ensure adequate vitamin D |
| DEXA scan | Baseline, 12-18 months | Assess BMD response |
| Alkaline phosphatase | Baseline | Rule out Paget disease |
| Renal function | Baseline | Assess renal status |
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Abaloparatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.